Lord’s Mark Industries says it was registered by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on September 24, 2026, as a manufacturer of an in-vitro diagnostic (IVD) portfolio. That is a reported regulatory milestone—not MHRA approval or endorsement of the products. The company’s planned UK sales and pathology-laboratory launch are future milestones, and a Great Britain registration does not establish access to Northern Ireland or allied-country markets.
What Lord’s Mark says it registered
A sponsored NDTV Profit report published October 5, 2026 says Lord’s Mark Industries Limited was registered as a manufacturer on September 24 for an IVD portfolio. The report lists four broad categories:
- Haematological cell analysers
- Clinical chemistry analysers
- Buffered sample diluents
- Instrument or analyser cleaning agents
It does not identify product models or trade names, device classes, or specific intended uses. The company’s 2025 IVD catalogue provides company-product context but does not independently establish which products were covered by the 2026 registration.
As an Amazon Associate I earn from qualifying purchases.
What MHRA registration does—and does not—mean
MHRA guidance says medical devices, including IVDs, must be registered before they are placed on the market in Great Britain: England, Wales and Scotland. The agency explicitly distinguishes registration from accreditation, certification, approval and endorsement. It is therefore inaccurate to describe the listed products as “MHRA-approved” on the basis of this announcement alone. See the MHRA guidance on registering medical devices to place on the market.
The announcement is sponsored content, and a device-specific Lord’s Mark IVD record was not located in the MHRA Public Access Registration Database (PARD) search reviewed for this article. PARD supports searches by registered manufacturer, device type using GMDN, and device name, but the reported portfolio registration should not be presented as independently confirmed at the device level. The MHRA Public Access Registration Database is the agency’s searchable database.
Which markets the registration covers
The relevant registration requirement described by the MHRA applies to Great Britain. Northern Ireland follows different medical-device requirements, so a claim of UK availability needs to account for that distinction. The MHRA’s UK medical-device guidance explains the geographic differences.
#1 Best Overall
- FDA-Approved & Clinically Trusted: The only oral fluid HIV self-test capable to detect both HIV-1 and HIV-2 antibodies. The same trusted test used by healthcare providers. Approved for use in individuals 14 years of age and older
- Quick & Easy Results in 20 Minutes: Just three simple steps and 20 minutes to know your HIV status, no lab visit or waiting required. Contact the OraSure support call center for confidential expert assistance and guidance if needed. FSA/HSA Eligible
- Pain-Free Oral Swab Testing: Uses a gentle gum swab; no needles, no discomfort, and no mess. Each kit includes: 1 OraQuick test device and vial, 1 Test Stand, 1 "HIV, Testing & Me" educational booklet, 1 instructional guide
- Confidential & Convenient At-Home Testing: Perform your test anytime, anywhere, with complete privacy. No appointments, waiting rooms, or follow-up visits. Ideal for individuals seeking discreet, self-directed HIV testing
- Sustainable & Reliable: Rebranded from OraQuick In-Home HIV Test with eco-friendly packaging; same trusted accuracy and performance as before.
Lord’s Mark’s announcement presents the UK as a platform for expansion into allied markets, but a Great Britain registration does not itself grant market access elsewhere. Each destination country’s requirements must be assessed separately; the announcement does not identify specific allied-country approvals or registrations.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallOutdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWhat Lord’s Mark plans next
According to the October 5 announcement, Lord’s Mark planned to begin commercial IVD sales in the UK in December 2026—about two months earlier than its previous schedule—and to start operating a pathology laboratory in January 2027. These were company plans, not completed outcomes as of the report date.
Rank #2
- Quick Results: Learn your blood type in just a couple of minutes with this easy-to-use testing kit
- Simple Interpretation: Easily understand your blood type group with clear and straightforward results
- Permanent Record: Keep as a permanent record of your blood type on the durable card for your records or safekeeping
- Reliable Accuracy: Offers a reliable and accurate way to learn your blood type using proven testing technology
- Convenient Home Use: Can be used conveniently at home without the need for laboratory visits
CEO and managing director Dr. Sachidanand Upadhyay said the IVD registration followed a separate registration for the company’s Renalyx haemodialysis system and described the plans as part of a broader diagnostics and healthcare platform. His statement reflects the company’s position; it does not independently verify registration status or future launch dates. A September 29, 2026 Hindustan Times report covered the separate Renalyx development, which should not be confused with the IVD portfolio registration.
Quick Recap
Best Value
- Tests for 5 STDs: An easy-to-use 5-Panel STD test with simple, fast, and private results. Simple HealthKit's 5-Panel STD Test screens for 5 STDs / STIs: Chlamydia, Gonorrhea, Trichomoniasis, HCV & Syphilis.
- Fast, Simple, Private: Getting tested has never been easier. Collect a urine & blood sample from the privacy of your home and send it to our lab for testing. Once the sample is received by our lab, your online results are typically available within 3 - 5 days.
- Free Follow-Up Care: Lab processing is included with your test purchase. If you receive a positive or abnormal test result, follow-up care is included. No extra charge. No hidden fees. It's that simple.
- Physician Approved, HSA / FSA Eligible, Test Intended for 18+ Only: Not Available in NY. Lab is CLIA Certified and CAP Accredited. Results delivered through a HIPAA-compliant portal.
- Fast, Simple, Private: Getting tested has never been easier. Collect a urine & blood sample from home and send it to our lab for testing. Once the sample is received by our lab, your online results are typically available within 3 - 5 days.
Rank #4
- FAST & EASY RESULTS IN 1 MINUTE – Simple at-home testing with clear results in as little as 60 seconds. No lab visits, no appointments, no waiting.
- PRIVATE & CONFIDENTIAL AT-HOME TESTING – Test in the comfort of your home with privacy and control from start to finish.
- OVER 99% ACCURATE - Clinically proven to deliver highly accurate results, giving you confidence in your test outcome.
- MORE ACCURATE THAN ORAL TESTS - Designed to provide greater confidence and clarity compared to oral fluid HIV tests.
- SATISFACTION GUARANTEED - If you experience any issues with your test, contact INSTI directly and we will resolve it quickly.
Rank #3
- BD Veritor System offers test assays that can be used to process samples provided to the lab in an appropriate transport medium
- The first CLIA-waived Digital Immunoassay (DIA), a new category of diagnostic tests where the assay and instrument work together to combine advances in detection particles, optical image recognition and interpretation algorithms to improve accuracy
- Advanced Particle Technology enhances sensitivity by using a proprietary process to produce highly stable modified colloidal metal particles, helping improve test performance
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
